Xiaofeng Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaofeng Ding has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Qian Tan
Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, Clinical College, Jiangsu University, Nanjing, China; Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China; Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, Clinical College, Nanjing University of Chinese Medicine, Nanjing, China
4 shared publications - Youjun Ding
Department of Vascular Surgery, Cardiovascular medical center, Nanjing Drum Tower Hospital, Clinical College, Jiangsu University, Nanjing, 210002, China
4 shared publications - Hao Zhang
Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing China
3 shared publications - Junchao Wu
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People’s Republic of China
3 shared publications Yongxian Lai
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
3 shared publications- Ping Yang
Department of Microsurgery, Jinhu County People's Hospital, NO.160 Shenhua Avenue, Jinhu County, Huai'an City, Jiangsu Province, China
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by MDPI AG in Preprints.org
Targeting Inflammation and Vascular Dysfunction in Androgenetic Alopecia: Emerging Therapeutic Opportunities and Future Perspectives
Androgenetic alopecia (AGA) is mainly characterized by androgen-dependent follicular miniaturization. However, increasing evidence suggests that inflammation, fibrosis and vascular changes may also affect the follicular microenvironment. This review summarizes the normal vascular and cellular regulation of the hair follicle and discusses how these processes may be altered in AGA. Human studies have identified perifollicular inflammation, reduced perfusion and changes in angiogenesis-related genes, but their causal roles remain unclear. Experimental studies further show close communication among dermal papilla cells, endothelial cells, immune cells and hair follicle stem cells. Current treatments mainly reduce androgen signaling or stimulate hair growth and may not fully address these microenvironmental changes. Emerging approaches, including anti-inflammatory treatments, nitric oxide and VEGF-based systems, microneedles, hydrogels and nano-enabled delivery, may regulate several pathways at the same time. However, most of these strategies remain preclinical. Future studies should clarify whether inflammation and vascular dysfunction are causes or consequences of follicular miniaturization and determine whether targeting these pathways can improve clinical outcomes in AGA.
- 7 October 2026
- Published by MDPI AG in Preprints.org
Open AccessTargeting Inflammation and Vascular Dysfunction in Androgenetic Alopecia: Emerging Therapeutic Opportunities and Future Perspectives
Androgenetic alopecia (AGA) is mainly characterized by androgen-dependent follicular miniaturization. However, increasing evidence suggests that inflammation, fibrosis and vascular changes may also affect the follicular microenvironment. This review summarizes the normal vascular and cellular regulation of the hair follicle and discusses how these processes may be altered in AGA. Human studies have identified perifollicular inflammation, reduced perfusion and changes in angiogenesis-related genes, but their causal roles remain unclear. Experimental studies further show close communication among dermal papilla cells, endothelial cells, immune cells and hair follicle stem cells. Current treatments mainly reduce androgen signaling or stimulate hair growth and may not fully address these microenvironmental changes. Emerging approaches, including anti-inflammatory treatments, nitric oxide and VEGF-based systems, microneedles, hydrogels and nano-enabled delivery, may regulate several pathways at the same time. However, most of these strategies remain preclinical. Future studies should clarify whether inflammation and vascular dysfunction are causes or consequences of follicular miniaturization and determine whether targeting these pathways can improve clinical outcomes in AGA.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
From Passive Cargo to Active Skeleton: A pH-Responsive Polysaccharide Hydrogel Integrating Dipotassium Glycyrrhizinate as a Dynamic Cross-Linking Node for Scarless Wound Healing
Traditional herbal-based wound dressings are often limited by low drug-loading capacity, inadequate infection control, and passive drug delivery. Here, we address these challenges by transforming dipotassium glycyrrhizinate (DG)─a natural herbal anti-inflammatory agent─from a conventional “passive cargo” into an active structural component of a polysaccharide hydrogel network. We developed a dynamically cross-linked hydrogel (HCC-DG-Cu) by integrating DG with hyaluronic acid (HA), chitosan (CS), and carboxymethyl cellulose (CMC) via hydrogen bonding, electrostatic interactions, and dynamic Cu2+ coordination. This design paradigm shift yields three key advances: (1) ultrahigh drug loading (∼55%, ≈30% higher than conventional polysaccharide hydrogels) by incorporating DG as a network-integrated building block rather than a physically loaded additive; (2) pH-responsive release (≈95% at pH 9.0 vs ≈54% at pH 5.5) leveraging Cu2+ coordination dynamics; (3) synergistic antibacterial activity (>90% inhibition against S. aureus and E. coli) and potent anti-inflammatory effects without conventional antibiotics. In an E. coli-infected full-thickness wound model, the HCC-DG-Cu hydrogel significantly accelerated wound closure, promoted orderly collagen deposition, enhanced angiogenesis (CD31+/VEGF+), and minimized scar formation─outcomes attributed to the sustained, microenvironment-modulating release of DG from the dynamic network. This work establishes a clear structure–function–therapeutic efficacy correlation and presents a generalizable strategy to upgrade passive herbal-loaded dressings into active, multifunctional regenerative platforms.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
From Passive Cargo to Active Skeleton: A pH-Responsive Polysaccharide Hydrogel Integrating Dipotassium Glycyrrhizinate as a Dynamic Cross-Linking Node for Scarless Wound Healing
Traditional herbal-based wound dressings are often limited by low drug-loading capacity, inadequate infection control, and passive drug delivery. Here, we address these challenges by transforming dipotassium glycyrrhizinate (DG)─a natural herbal anti-inflammatory agent─from a conventional “passive cargo” into an active structural component of a polysaccharide hydrogel network. We developed a dynamically cross-linked hydrogel (HCC-DG-Cu) by integrating DG with hyaluronic acid (HA), chitosan (CS), and carboxymethyl cellulose (CMC) via hydrogen bonding, electrostatic interactions, and dynamic Cu2+ coordination. This design paradigm shift yields three key advances: (1) ultrahigh drug loading (∼55%, ≈30% higher than conventional polysaccharide hydrogels) by incorporating DG as a network-integrated building block rather than a physically loaded additive; (2) pH-responsive release (≈95% at pH 9.0 vs ≈54% at pH 5.5) leveraging Cu2+ coordination dynamics; (3) synergistic antibacterial activity (>90% inhibition against S. aureus and E. coli) and potent anti-inflammatory effects without conventional antibiotics. In an E. coli-infected full-thickness wound model, the HCC-DG-Cu hydrogel significantly accelerated wound closure, promoted orderly collagen deposition, enhanced angiogenesis (CD31+/VEGF+), and minimized scar formation─outcomes attributed to the sustained, microenvironment-modulating release of DG from the dynamic network. This work establishes a clear structure–function–therapeutic efficacy correlation and presents a generalizable strategy to upgrade passive herbal-loaded dressings into active, multifunctional regenerative platforms.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
Engineered Exosomes Co-Delivering EGF and FGF Ameliorate Androgenetic Alopecia in a Mouse Model
Background: Androgenetic alopecia (AGA) is characterized by hair follicle miniaturization and growth factor deficiency. However, conventional therapies such as minoxidil and finasteride fail to restore the pathological follicular microenvironment, highlighting the urgent need for novel therapeutic strategies. Epidermal growth factor (EGF) and fibroblast growth factor (FGF) are key regulators of hair follicle regeneration, yet their expression is downregulated in the follicular microenvironment of AGA patients. Methods: This study validated the expression profile of growth factors in hair follicles of AGA patients through clinical sample analysis. Subsequently, dual‑factor engineered exosomes (EXO‑EGF/FGF) loaded with EGF and FGF were constructed using LAMP2B fusion engineering technology with 293T cells as donor cells. EXO‑EGF/FGF was characterized by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The regulatory effects of EXO‑EGF/FGF on human dermal papilla cells (HDPCs) were evaluated in vitro. An androgen‑induced AGA mouse model was established to assess the therapeutic efficacy and safety of EXO‑EGF/FGF in vivo. Results: Clinical sample analysis confirmed that the expression of EGF and FGF was significantly downregulated in dermal papilla cells of AGA patients, leading to reduced expression of NOTCH signaling pathway proteins associated with hair follicle regeneration. TEM and NTA results demonstrated that EXO‑EGF/FGF exhibited exosomal morphology, with significantly higher expression levels of EGF and FGF than natural exosomes. In vitro experiments revealed that EXO‑EGF/FGF promoted the proliferation and migration of HDPCs by reactivating the cell cycle and enhancing migration‑related programs. In the AGA mouse model, EXO‑EGF/FGF effectively restored hair coverage density and follicular structural integrity without inducing immunogenic reactions or systemic toxicity, and significantly increased the number of anagen‑phase hair follicles in post‑treatment tissues. Conclusion: This study demonstrated that LAMP2B‑engineered EXO‑EGF/FGF acted on follicular cells to repair the pathological microenvironment in AGA. This strategy overcame the inherent limitations of conventional therapies and natural exosomes, offering a novel, safe, and clinically translatable therapeutic approach for AGA treatment.
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
Open AccessEngineered Exosomes Co-Delivering EGF and FGF Ameliorate Androgenetic Alopecia in a Mouse Model
Background: Androgenetic alopecia (AGA) is characterized by hair follicle miniaturization and growth factor deficiency. However, conventional therapies such as minoxidil and finasteride fail to restore the pathological follicular microenvironment, highlighting the urgent need for novel therapeutic strategies. Epidermal growth factor (EGF) and fibroblast growth factor (FGF) are key regulators of hair follicle regeneration, yet their expression is downregulated in the follicular microenvironment of AGA patients. Methods: This study validated the expression profile of growth factors in hair follicles of AGA patients through clinical sample analysis. Subsequently, dual‑factor engineered exosomes (EXO‑EGF/FGF) loaded with EGF and FGF were constructed using LAMP2B fusion engineering technology with 293T cells as donor cells. EXO‑EGF/FGF was characterized by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The regulatory effects of EXO‑EGF/FGF on human dermal papilla cells (HDPCs) were evaluated in vitro. An androgen‑induced AGA mouse model was established to assess the therapeutic efficacy and safety of EXO‑EGF/FGF in vivo. Results: Clinical sample analysis confirmed that the expression of EGF and FGF was significantly downregulated in dermal papilla cells of AGA patients, leading to reduced expression of NOTCH signaling pathway proteins associated with hair follicle regeneration. TEM and NTA results demonstrated that EXO‑EGF/FGF exhibited exosomal morphology, with significantly higher expression levels of EGF and FGF than natural exosomes. In vitro experiments revealed that EXO‑EGF/FGF promoted the proliferation and migration of HDPCs by reactivating the cell cycle and enhancing migration‑related programs. In the AGA mouse model, EXO‑EGF/FGF effectively restored hair coverage density and follicular structural integrity without inducing immunogenic reactions or systemic toxicity, and significantly increased the number of anagen‑phase hair follicles in post‑treatment tissues. Conclusion: This study demonstrated that LAMP2B‑engineered EXO‑EGF/FGF acted on follicular cells to repair the pathological microenvironment in AGA. This strategy overcame the inherent limitations of conventional therapies and natural exosomes, offering a novel, safe, and clinically translatable therapeutic approach for AGA treatment.
- 8 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 342 (Pt 2) , 150167
Multifunctional hydrogel based on oxidized sodium alginate and carboxymethyl chitosan delivers minoxidil loaded liposomes for the treatment of androgenetic alopecia
- 8 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 342 (Pt 2) , 150167
Multifunctional hydrogel based on oxidized sodium alginate and carboxymethyl chitosan delivers minoxidil loaded liposomes for the treatment of androgenetic alopecia
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , 2139238
Pachymic Acid Accelerated Diabetic Ulcer Healing by Enhancing Macrophage Efferocytosis via the MEK/ERK/TGF β 1 Signaling Axis
Objective: Diabetic ulcers (DUs) are severe and prevalent complications of type 2 diabetes, characterized by impaired macrophage efferocytosis and sustained chronic inflammation within the wound microenvironment. Pachymic acid (PA) is a natural triterpenoid with potent anti‐inflammatory and immunomodulatory properties. This research is aimed at exploring whether PA facilitates healing of DUs by activating the MEK/ERK/TGF β 1 signaling axis to restore macrophage efferocytosis. Methods: In vitro, cell viability was evaluated using CCK‐8 assay. An inflammatory macrophage model was established via LPS/IFN‐ γ induction to assess the impact of PA on reactive oxygen species (ROS) and proinflammatory mediator levels. Macrophages were cocultured with apoptotic cells to evaluate efferocytosis. Transcriptome sequencing, bioinformatics analyses, and RT‐qPCR validation were conducted on PA‐treated macrophages to explore the core regulatory networks, whereas western blot was utilized to verify the underlying proefferocytotic mechanisms. In vivo, a diabetic wound (DW) mouse model was established and treated with PA. Western blot, immunofluorescence, and histological staining were performed to evaluate macrophage polarization, the activation of the MEK/ERK/TGF β 1 pathway, angiogenesis, and the expression levels of efferocytosis‐related proteins. Results: In vitro experiments demonstrated that PA exhibited minimal cytotoxicity, significantly reduced ROS levels, and suppressed the secretion of proinflammatory mediators in macrophages while enhancing their ability to engulf apoptotic cells. Transcriptomic profiling, RT‐qPCR validation, and protein–protein interaction network analyses revealed that PA′s regulatory targets were enriched in efferocytosis and the MEK/ERK pathway. In the DW mouse model, PA treatment alleviated inflammatory cell infiltration, promoted collagen deposition and angiogenesis, improved the SPOT skin wound score, and accelerated wound closure. Both in vitro and in vivo analyses confirmed that PA upregulated the expression of P‐MEK1/2, P‐ERK1/2, and TGF β 1, and key efferocytosis receptors, which drove the phenotypic transition of wound macrophages from a proinflammatory state to an anti‐inflammatory and restorative state. Conclusion: PA upregulated the expression of vital efferocytosis receptors by activating the MEK/ERK/TGF β 1 signaling axis, enhancing macrophage efferocytosis, and alleviating local oxidative stress. This study elucidated the mechanism of PA in treating DUs, providing a theoretical foundation for its clinical translation as a novel drug to promote DW healing.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , 2139238
Open AccessPachymic Acid Accelerated Diabetic Ulcer Healing by Enhancing Macrophage Efferocytosis via the MEK/ERK/TGF β 1 Signaling Axis
Objective: Diabetic ulcers (DUs) are severe and prevalent complications of type 2 diabetes, characterized by impaired macrophage efferocytosis and sustained chronic inflammation within the wound microenvironment. Pachymic acid (PA) is a natural triterpenoid with potent anti‐inflammatory and immunomodulatory properties. This research is aimed at exploring whether PA facilitates healing of DUs by activating the MEK/ERK/TGF β 1 signaling axis to restore macrophage efferocytosis. Methods: In vitro, cell viability was evaluated using CCK‐8 assay. An inflammatory macrophage model was established via LPS/IFN‐ γ induction to assess the impact of PA on reactive oxygen species (ROS) and proinflammatory mediator levels. Macrophages were cocultured with apoptotic cells to evaluate efferocytosis. Transcriptome sequencing, bioinformatics analyses, and RT‐qPCR validation were conducted on PA‐treated macrophages to explore the core regulatory networks, whereas western blot was utilized to verify the underlying proefferocytotic mechanisms. In vivo, a diabetic wound (DW) mouse model was established and treated with PA. Western blot, immunofluorescence, and histological staining were performed to evaluate macrophage polarization, the activation of the MEK/ERK/TGF β 1 pathway, angiogenesis, and the expression levels of efferocytosis‐related proteins. Results: In vitro experiments demonstrated that PA exhibited minimal cytotoxicity, significantly reduced ROS levels, and suppressed the secretion of proinflammatory mediators in macrophages while enhancing their ability to engulf apoptotic cells. Transcriptomic profiling, RT‐qPCR validation, and protein–protein interaction network analyses revealed that PA′s regulatory targets were enriched in efferocytosis and the MEK/ERK pathway. In the DW mouse model, PA treatment alleviated inflammatory cell infiltration, promoted collagen deposition and angiogenesis, improved the SPOT skin wound score, and accelerated wound closure. Both in vitro and in vivo analyses confirmed that PA upregulated the expression of P‐MEK1/2, P‐ERK1/2, and TGF β 1, and key efferocytosis receptors, which drove the phenotypic transition of wound macrophages from a proinflammatory state to an anti‐inflammatory and restorative state. Conclusion: PA upregulated the expression of vital efferocytosis receptors by activating the MEK/ERK/TGF β 1 signaling axis, enhancing macrophage efferocytosis, and alleviating local oxidative stress. This study elucidated the mechanism of PA in treating DUs, providing a theoretical foundation for its clinical translation as a novel drug to promote DW healing.
- Open Access
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40956
Omentin-1 promotes wound healing in diabetic mice by improving vascular endothelial cell function
Diabetes is a metabolic disease that affects global human health, with 25% of diabetic patients suffering from chronic non-healing ulcers. Omentin-1, also referred to as intelectin-1 and encoded by the itln1 gene, is a recently discovered adipokine that modulates inflammation, cellular activities, and vascular tone. Research indicates that omentin-1 provides protective benefits in several conditions, including atherosclerosis and diabetic retinopathy. Nevertheless, the therapeutic potential of omentin-1 in promoting diabetic wound healing is still not well understood. Our results revealed a significant decrease in ITLN1 levels in the cutaneous tissues of diabetic mice. Subcutaneous injection of omentin-1 reduced endothelial cell apoptosis, enhanced angiogenesis, and accelerated wound repair in diabetic mice. In vitro studies demonstrated that omentin-1 upregulated VEGF expression in endothelial cells, improved endothelial function under high-glucose conditions, reduced high glucose-induced endothelial apoptosis, and promoted endothelial tube formation. Further mechanistic studies revealed that omentin-1 improved endothelial function and promoted angiogenesis under high-glucose conditions by mediating the PI3K/AKT/FOXO1 pathway. Our results suggest that omentin-1 is a potential adjunct or therapeutic agent for treating chronic non-healing diabetic wounds by enhancing endothelial cell function and promoting vascularization.
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40956
Open AccessOmentin-1 promotes wound healing in diabetic mice by improving vascular endothelial cell function
Diabetes is a metabolic disease that affects global human health, with 25% of diabetic patients suffering from chronic non-healing ulcers. Omentin-1, also referred to as intelectin-1 and encoded by the itln1 gene, is a recently discovered adipokine that modulates inflammation, cellular activities, and vascular tone. Research indicates that omentin-1 provides protective benefits in several conditions, including atherosclerosis and diabetic retinopathy. Nevertheless, the therapeutic potential of omentin-1 in promoting diabetic wound healing is still not well understood. Our results revealed a significant decrease in ITLN1 levels in the cutaneous tissues of diabetic mice. Subcutaneous injection of omentin-1 reduced endothelial cell apoptosis, enhanced angiogenesis, and accelerated wound repair in diabetic mice. In vitro studies demonstrated that omentin-1 upregulated VEGF expression in endothelial cells, improved endothelial function under high-glucose conditions, reduced high glucose-induced endothelial apoptosis, and promoted endothelial tube formation. Further mechanistic studies revealed that omentin-1 improved endothelial function and promoted angiogenesis under high-glucose conditions by mediating the PI3K/AKT/FOXO1 pathway. Our results suggest that omentin-1 is a potential adjunct or therapeutic agent for treating chronic non-healing diabetic wounds by enhancing endothelial cell function and promoting vascularization.
- Open Access
- 8 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102253
Bioinformatics analysis of immune infiltration and cell cycle hub genes in atopic dermatitis
- 8 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102253
Open AccessBioinformatics analysis of immune infiltration and cell cycle hub genes in atopic dermatitis
- Open Access
- 1 June 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8497-8528
Biological and Bioinspired Vesicles for Wound Healing: Insights, Advances and Challenges
Millions of people suffer traumatic injuries and surgical procedures each year, making effective wound management very important. Benign wound repair is essential for structural and functional recovery of damaged tissues. Natural biological vesicles have emerged as attractive candidates for accelerating wound healing due to their endogenous nature and distinctive biological properties. However, obstacles such as low separation yields, potential safety concerns, and unsatisfactory production restrict their continuous application. In recent years, bioinspired materials and technologies have played an important role in the field of remodeling wound healing. Bioinspired vesicles function by effectively transporting therapeutic substances through mimicking the chemical and biological properties in nature, and can be modified and prepared through a variety of advanced techniques such as genetic engineering, chemical modification, and physical techniques, and are good substitutes for natural vesicles. Therefore, integrating bioinspired design into vesicles to promote wound healing can improve the curative effect while maintaining good safety, which helps to accelerate the clinical transformation of vesicles. This review discusses the latest progress, barriers to clinical transformation, and future development directions of biological and bioinspired vesicles for wound healing.
- 1 June 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8497-8528
Open AccessBiological and Bioinspired Vesicles for Wound Healing: Insights, Advances and Challenges
Millions of people suffer traumatic injuries and surgical procedures each year, making effective wound management very important. Benign wound repair is essential for structural and functional recovery of damaged tissues. Natural biological vesicles have emerged as attractive candidates for accelerating wound healing due to their endogenous nature and distinctive biological properties. However, obstacles such as low separation yields, potential safety concerns, and unsatisfactory production restrict their continuous application. In recent years, bioinspired materials and technologies have played an important role in the field of remodeling wound healing. Bioinspired vesicles function by effectively transporting therapeutic substances through mimicking the chemical and biological properties in nature, and can be modified and prepared through a variety of advanced techniques such as genetic engineering, chemical modification, and physical techniques, and are good substitutes for natural vesicles. Therefore, integrating bioinspired design into vesicles to promote wound healing can improve the curative effect while maintaining good safety, which helps to accelerate the clinical transformation of vesicles. This review discusses the latest progress, barriers to clinical transformation, and future development directions of biological and bioinspired vesicles for wound healing.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 4656485
Revealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation
Background: Shikonin (SHK) possesses extensive pharmacological effects including antimicrobial and anti‐inflammatory properties for diabetic wound (DW), while its molecular mechanism remains to be clarified. In this study, we investigated the potential mechanisms of SHK in treating DW by combining network pharmacology and in vitro experiments. Methods: We obtained potential targets for SHK and DW from the publicly available database. Based on the interaction network and conducting GO and KEGG pathway enrichment analysis, we constructed a target pathway network to explore the relationship between SHK and DW. To validate the mechanism of SHK, we established an in vitro experimental model. Results: Sixty intersecting targets between SHK and DW were obtained, and the top 10 targets of the protein–protein interaction (PPI) network included AKT1, SRC, EGFR, CASP3, MMP9, PPARG, ESR1, ANXA5, MMP2, and JAK2. Based on target–pathway networks, the PI3K‐AKT signaling pathway was found to be a signaling pathway with low p value in enrichment analysis. In vitro experiments revealed that SHK significantly promoted angiogenesis. Meanwhile, SHK could inhibit the high glucose‐induced human umbilical vein endothelial cell dysfunction through regulating the PI3K‐AKT pathway. Conclusion: This study initially revealed the molecular mechanism of SHK in DW by multitarget and multipathway. The PI3K–AKT signaling pathway, MAPK signaling pathway, and AGE‐RAGE signaling pathways may be the main pathways of SHK in treating DW.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 4656485
Open AccessRevealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation
Background: Shikonin (SHK) possesses extensive pharmacological effects including antimicrobial and anti‐inflammatory properties for diabetic wound (DW), while its molecular mechanism remains to be clarified. In this study, we investigated the potential mechanisms of SHK in treating DW by combining network pharmacology and in vitro experiments. Methods: We obtained potential targets for SHK and DW from the publicly available database. Based on the interaction network and conducting GO and KEGG pathway enrichment analysis, we constructed a target pathway network to explore the relationship between SHK and DW. To validate the mechanism of SHK, we established an in vitro experimental model. Results: Sixty intersecting targets between SHK and DW were obtained, and the top 10 targets of the protein–protein interaction (PPI) network included AKT1, SRC, EGFR, CASP3, MMP9, PPARG, ESR1, ANXA5, MMP2, and JAK2. Based on target–pathway networks, the PI3K‐AKT signaling pathway was found to be a signaling pathway with low p value in enrichment analysis. In vitro experiments revealed that SHK significantly promoted angiogenesis. Meanwhile, SHK could inhibit the high glucose‐induced human umbilical vein endothelial cell dysfunction through regulating the PI3K‐AKT pathway. Conclusion: This study initially revealed the molecular mechanism of SHK in DW by multitarget and multipathway. The PI3K–AKT signaling pathway, MAPK signaling pathway, and AGE‐RAGE signaling pathways may be the main pathways of SHK in treating DW.
- Open Access
- 15 November 2023
- Published by Taylor & Francis in Annals of Medicine
- Vol. 55 (2) , 2280811
Mechanisms of resveratrol against diabetic wound by network pharmacology and experimental validation
Resveratrol (RSV) that possesses anti-oxidative, anti-inflammatory, and pro-angiogenic effects is an effective drug for diabetic wound (DW), while its pharmacological mechanism remains to be elucidated. In this study, we apply network pharmacology and experimental validation approach to reveal the potential mechanism of RSV against DW. We obtained potential targets for RSV and DW from the publicly available database. Using interaction networks and conducting GO and KEGG pathway enrichment analyses, we constructed target-pathway networks to explore the relationship between RSV and DW. To validate the pharmacological mechanism of RSV, we induced the DW model. Ninety overlapped targets between RSV and DW were obtained, and the hub genes of the PPI network included TNF, IL-6, CASP3, MAPK3, VEGFA, IL-1β, AKT1, and JUN. Based on target-pathway networks, the AGE-RAGE signalling pathway was involved in the RSV treatment of DW. Furthermore, in vivo experiments revealed that RSV significantly promoted wound healing in diabetic mice and attenuated the expression of pro-inflammatory cytokines in wound tissue. Meanwhile, RSV could inhibit the AGE-RAGE signalling pathway and thus reduce the activation of NF-κB. This study initially revealed the biological mechanism of RSV for treating DW through multi-target and multi-pathway. AGE-RAGE, FoxO, MAPK, PI3K-AKT and other signalling pathways may be the main pathways of RSV in treating DW. RSV reduces the inflammatory response by inhibiting the AGE-RAGE signalling pathway, which in turn promotes DW healing.
- 15 November 2023
- Published by Taylor & Francis in Annals of Medicine
- Vol. 55 (2) , 2280811
Open AccessMechanisms of resveratrol against diabetic wound by network pharmacology and experimental validation
Resveratrol (RSV) that possesses anti-oxidative, anti-inflammatory, and pro-angiogenic effects is an effective drug for diabetic wound (DW), while its pharmacological mechanism remains to be elucidated. In this study, we apply network pharmacology and experimental validation approach to reveal the potential mechanism of RSV against DW. We obtained potential targets for RSV and DW from the publicly available database. Using interaction networks and conducting GO and KEGG pathway enrichment analyses, we constructed target-pathway networks to explore the relationship between RSV and DW. To validate the pharmacological mechanism of RSV, we induced the DW model. Ninety overlapped targets between RSV and DW were obtained, and the hub genes of the PPI network included TNF, IL-6, CASP3, MAPK3, VEGFA, IL-1β, AKT1, and JUN. Based on target-pathway networks, the AGE-RAGE signalling pathway was involved in the RSV treatment of DW. Furthermore, in vivo experiments revealed that RSV significantly promoted wound healing in diabetic mice and attenuated the expression of pro-inflammatory cytokines in wound tissue. Meanwhile, RSV could inhibit the AGE-RAGE signalling pathway and thus reduce the activation of NF-κB. This study initially revealed the biological mechanism of RSV for treating DW through multi-target and multi-pathway. AGE-RAGE, FoxO, MAPK, PI3K-AKT and other signalling pathways may be the main pathways of RSV in treating DW. RSV reduces the inflammatory response by inhibiting the AGE-RAGE signalling pathway, which in turn promotes DW healing.